This german study network was set up to take account of some of the recent developments in molecular medicine in the treatment of patients with metastatic breast cancer.
It is an academic registry and translational diagnostics study with the aim to build a healthcare research data base with the objective:. In phase I, only advanced breast cancer patients are included. In phases II and III the data base should be expanded by neo- adjuvant breast cancer patients and in the end by other tumor entities.
The protocol was amended and updated in March reaching Phase II to enroll patients with the diagnosis of early breast cancer in the neoadjuvant or adjuvant curative treatment setting. If you are interested to take part in the study. Some fundamental backgrund information:. Your personal biomarker profile will be given to your treating phyisician, if you wish so. Then your treatment may be changed or you can be introduced in other clinical studies which show a good prognosis according to your biomarker profile.
All treatements and collected data will be treated confidentially. Bei Studieneinschluss und bei jedem Therapiewechsel werden 5 Blutproben in die zentrale Biobank geschickt. Des Weiteren werden Tumorproben, soweit vorhanden, angefordert. Unter info praegnant. Des Weiteren sind alle Informationen unter www. There are different factors which influence the prognosis and possible treatment side-effects. Few of them could have a prognostic significance for patients with metastatic breast cancer, even if they are not yet used much in routine clinical practice.
Most of the current understanding of molecular patterns in breast cancer was gained from patients with primary breast cancer without metastatic disease. Breast cancer is typically subdivided in.
